5 minute read
Jul. 27, 2022

DNL201: a CNS-Penetrating Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor


oral LRRK2 kinase inhibitor Ph. I completed in Parkinson’s Disease HTS, SBDD, and CNS-focused opt. Sci. Transl. Med. Denali Therapeutics Inc., South San Francisco, CA

Drug Hunter Team

Context. DNL201 (Denali Therapeutics) is an oral, CNS-penetrating, ATP-competitive leucine-rich repeat kinase 2 (LRRK2) inhibitor being developed for Parkinson’s disease (PD) . PD remains incurable; current treatment options only alleviate disease symptoms and do not prevent progression. Due to its well known involvement in familial and even [...]



Other molecules you may be interested in